Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery
Latest Information Update: 19 Aug 2026
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Gallium 68-DOTATATE
- Indications Gastro-enteropancreatic neuroendocrine tumour; Liver metastases
- Focus Therapeutic Use
Most Recent Events
- 11 Aug 2026 Planned End Date changed from 1 Sep 2027 to 1 May 2027.
- 11 Aug 2026 Planned primary completion date changed from 1 Jul 2026 to 1 Nov 2026.
- 11 Aug 2026 Status changed from recruiting to active, no longer recruiting.